Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab Nanolipo Article Swipe
Gazala Layas
,
Mohammad Isreb
,
Nader Ghaderi
,
Fanila Shahzad
,
Pouria Akhbari
,
Diana Anderson
,
Andrew Wright
,
Mojgan Najafzadeh
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.54536/ajlsi.v4i1.3268
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.54536/ajlsi.v4i1.3268
Psoriasis is an immune-mediated disease affecting the skin and joints. biologic treatments are often used in moderate to severe cases, administered as a monotherapy or in combination with other treatments. Liposomes are versatile and can enhance drug retention, reducing systemic side effects, and are used for therapy and research. This research study aimed to investigate the Geno toxicity of Secukinumab, an ideal biologic treatment for psoriasis (a human IgG1k antibody, anti-IL17A), in bulk and liposome nanoparticles on the lymphocytes of psoriatic patients in comparison with healthy persons. Geno toxicity of Secukinumab in bulk and liposomal form was evaluated and compared by using the Comet and micronucleus assays. From assays, it was demonstrated that Secukinumab in both forms did not exhibit Geno toxicity and reduced DNA damage following the treatment of psoriatic patient lymphocytes and healthy individual’s lymphocytes with Secukinumab bulk and liposomes format. Secukinumab used (2.1 and 2.8 µg/mL) with two different concentrations, and effectively decreased DNA damage induced by H2O2 in both groups to almost the negative control level. Secukinumab bulk and liposome form markedly reduced the H2O2-induced damage and proficiently diminished its adverse effects both in the Comet (p<0.0001) and micronucleus as-says (p<0.01). Overall, Secukinumab in both forms showed anti-genotoxic and protective effects by expressing its potential to reduce DNA damage produced by oxidative stress and it was observed that it would not induce any further damage in the lymphocytes of healthy individuals and patients.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.54536/ajlsi.v4i1.3268
- https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411355755
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411355755Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.54536/ajlsi.v4i1.3268Digital Object Identifier
- Title
-
Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab NanolipoWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-06-15Full publication date if available
- Authors
-
Gazala Layas, Mohammad Isreb, Nader Ghaderi, Fanila Shahzad, Pouria Akhbari, Diana Anderson, Andrew Wright, Mojgan NajafzadehList of authors in order
- Landing page
-
https://doi.org/10.54536/ajlsi.v4i1.3268Publisher landing page
- PDF URL
-
https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386Direct OA link when available
- Concepts
-
Secukinumab, Bioavailability, Medicine, Liposome, Dermatology, Pharmacology, Psoriasis, Psoriatic arthritis, Chemistry, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411355755 |
|---|---|
| doi | https://doi.org/10.54536/ajlsi.v4i1.3268 |
| ids.doi | https://doi.org/10.54536/ajlsi.v4i1.3268 |
| ids.openalex | https://openalex.org/W4411355755 |
| fwci | 0.0 |
| type | article |
| title | Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab Nanolipo |
| biblio.issue | 1 |
| biblio.volume | 4 |
| biblio.last_page | 35 |
| biblio.first_page | 27 |
| topics[0].id | https://openalex.org/T14099 |
| topics[0].field.id | https://openalex.org/fields/16 |
| topics[0].field.display_name | Chemistry |
| topics[0].score | 0.8984000086784363 |
| topics[0].domain.id | https://openalex.org/domains/3 |
| topics[0].domain.display_name | Physical Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1605 |
| topics[0].subfield.display_name | Organic Chemistry |
| topics[0].display_name | Synthesis and Characterization of Heterocyclic Compounds |
| topics[1].id | https://openalex.org/T10274 |
| topics[1].field.id | https://openalex.org/fields/16 |
| topics[1].field.display_name | Chemistry |
| topics[1].score | 0.8931999802589417 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1605 |
| topics[1].subfield.display_name | Organic Chemistry |
| topics[1].display_name | Synthesis and biological activity |
| topics[2].id | https://openalex.org/T10469 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.8885999917984009 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Psoriasis: Treatment and Pathogenesis |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779786854 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9886308908462524 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7444755 |
| concepts[0].display_name | Secukinumab |
| concepts[1].id | https://openalex.org/C181389837 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7292405962944031 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q461809 |
| concepts[1].display_name | Bioavailability |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.6284370422363281 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C185154212 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5985642671585083 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q410454 |
| concepts[3].display_name | Liposome |
| concepts[4].id | https://openalex.org/C16005928 |
| concepts[4].level | 1 |
| concepts[4].score | 0.3793025016784668 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[4].display_name | Dermatology |
| concepts[5].id | https://openalex.org/C98274493 |
| concepts[5].level | 1 |
| concepts[5].score | 0.330122709274292 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[5].display_name | Pharmacology |
| concepts[6].id | https://openalex.org/C2780564577 |
| concepts[6].level | 2 |
| concepts[6].score | 0.2696376442909241 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q179945 |
| concepts[6].display_name | Psoriasis |
| concepts[7].id | https://openalex.org/C2776260265 |
| concepts[7].level | 3 |
| concepts[7].score | 0.23213502764701843 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q511097 |
| concepts[7].display_name | Psoriatic arthritis |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.20292925834655762 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| concepts[9].id | https://openalex.org/C55493867 |
| concepts[9].level | 1 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[9].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/secukinumab |
| keywords[0].score | 0.9886308908462524 |
| keywords[0].display_name | Secukinumab |
| keywords[1].id | https://openalex.org/keywords/bioavailability |
| keywords[1].score | 0.7292405962944031 |
| keywords[1].display_name | Bioavailability |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.6284370422363281 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/liposome |
| keywords[3].score | 0.5985642671585083 |
| keywords[3].display_name | Liposome |
| keywords[4].id | https://openalex.org/keywords/dermatology |
| keywords[4].score | 0.3793025016784668 |
| keywords[4].display_name | Dermatology |
| keywords[5].id | https://openalex.org/keywords/pharmacology |
| keywords[5].score | 0.330122709274292 |
| keywords[5].display_name | Pharmacology |
| keywords[6].id | https://openalex.org/keywords/psoriasis |
| keywords[6].score | 0.2696376442909241 |
| keywords[6].display_name | Psoriasis |
| keywords[7].id | https://openalex.org/keywords/psoriatic-arthritis |
| keywords[7].score | 0.23213502764701843 |
| keywords[7].display_name | Psoriatic arthritis |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.20292925834655762 |
| keywords[8].display_name | Chemistry |
| language | en |
| locations[0].id | doi:10.54536/ajlsi.v4i1.3268 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4387282411 |
| locations[0].source.issn | 2833-1397 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2833-1397 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | American Journal of Life Science and Innovation |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | American Journal of Life Science and Innovation |
| locations[0].landing_page_url | https://doi.org/10.54536/ajlsi.v4i1.3268 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5094118382 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Gazala Layas |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I139894009 |
| authorships[0].affiliations[0].raw_affiliation_string | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[0].institutions[0].id | https://openalex.org/I139894009 |
| authorships[0].institutions[0].ror | https://ror.org/00vs8d940 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I139894009 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | University of Bradford |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Gazala Layas |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[1].author.id | https://openalex.org/A5029861563 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4042-3940 |
| authorships[1].author.display_name | Mohammad Isreb |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I139894009 |
| authorships[1].affiliations[0].raw_affiliation_string | School of Pharmacy, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK |
| authorships[1].institutions[0].id | https://openalex.org/I139894009 |
| authorships[1].institutions[0].ror | https://ror.org/00vs8d940 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I139894009 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | University of Bradford |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mohammad Isreb |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | School of Pharmacy, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK |
| authorships[2].author.id | https://openalex.org/A5065451603 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Nader Ghaderi |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210115367, https://openalex.org/I4210166758 |
| authorships[2].affiliations[0].raw_affiliation_string | Bradford Teaching Hospitals NHS Foundation Trust, St Luke's Hospital, Little Horton Lane, BD5 0NA, UK |
| authorships[2].institutions[0].id | https://openalex.org/I4210166758 |
| authorships[2].institutions[0].ror | https://ror.org/05gekvn04 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210166758 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | Bradford Teaching Hospitals NHS Foundation Trust |
| authorships[2].institutions[1].id | https://openalex.org/I4210115367 |
| authorships[2].institutions[1].ror | https://ror.org/02ajrkx50 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210115367, https://openalex.org/I4210166758 |
| authorships[2].institutions[1].country_code | GB |
| authorships[2].institutions[1].display_name | St. Luke's Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Nader Ghaderi |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Bradford Teaching Hospitals NHS Foundation Trust, St Luke's Hospital, Little Horton Lane, BD5 0NA, UK |
| authorships[3].author.id | https://openalex.org/A5018919407 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7376-945X |
| authorships[3].author.display_name | Fanila Shahzad |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I139894009 |
| authorships[3].affiliations[0].raw_affiliation_string | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[3].institutions[0].id | https://openalex.org/I139894009 |
| authorships[3].institutions[0].ror | https://ror.org/00vs8d940 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I139894009 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | University of Bradford |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Fanila Shahzad |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[4].author.id | https://openalex.org/A5052074204 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4127-9058 |
| authorships[4].author.display_name | Pouria Akhbari |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I23923803 |
| authorships[4].affiliations[0].raw_affiliation_string | Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, EX2 5DW, UK |
| authorships[4].institutions[0].id | https://openalex.org/I23923803 |
| authorships[4].institutions[0].ror | https://ror.org/03yghzc09 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I23923803 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | University of Exeter |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Pouria Akhbari |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, EX2 5DW, UK |
| authorships[5].author.id | https://openalex.org/A5001390311 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9673-0398 |
| authorships[5].author.display_name | Diana Anderson |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I139894009 |
| authorships[5].affiliations[0].raw_affiliation_string | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[5].institutions[0].id | https://openalex.org/I139894009 |
| authorships[5].institutions[0].ror | https://ror.org/00vs8d940 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I139894009 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | University of Bradford |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Diana Anderson |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[6].author.id | https://openalex.org/A5101400592 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-6072-5148 |
| authorships[6].author.display_name | Andrew Wright |
| authorships[6].countries | GB |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210115367, https://openalex.org/I4210166758 |
| authorships[6].affiliations[0].raw_affiliation_string | Bradford Teaching Hospitals NHS Foundation Trust, St Luke's Hospital, Little Horton Lane, BD5 0NA, UK |
| authorships[6].institutions[0].id | https://openalex.org/I4210166758 |
| authorships[6].institutions[0].ror | https://ror.org/05gekvn04 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210166758 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | Bradford Teaching Hospitals NHS Foundation Trust |
| authorships[6].institutions[1].id | https://openalex.org/I4210115367 |
| authorships[6].institutions[1].ror | https://ror.org/02ajrkx50 |
| authorships[6].institutions[1].type | healthcare |
| authorships[6].institutions[1].lineage | https://openalex.org/I4210115367, https://openalex.org/I4210166758 |
| authorships[6].institutions[1].country_code | GB |
| authorships[6].institutions[1].display_name | St. Luke's Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Andrew Wright |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Bradford Teaching Hospitals NHS Foundation Trust, St Luke's Hospital, Little Horton Lane, BD5 0NA, UK |
| authorships[7].author.id | https://openalex.org/A5001995352 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-2749-4595 |
| authorships[7].author.display_name | Mojgan Najafzadeh |
| authorships[7].countries | GB |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I139894009 |
| authorships[7].affiliations[0].raw_affiliation_string | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| authorships[7].institutions[0].id | https://openalex.org/I139894009 |
| authorships[7].institutions[0].ror | https://ror.org/00vs8d940 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I139894009 |
| authorships[7].institutions[0].country_code | GB |
| authorships[7].institutions[0].display_name | University of Bradford |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Mojgan Najafzadeh |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | School of Life Sciences, University of Bradford, Bradford, BD7 1DP, UK |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab Nanolipo |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T14099 |
| primary_topic.field.id | https://openalex.org/fields/16 |
| primary_topic.field.display_name | Chemistry |
| primary_topic.score | 0.8984000086784363 |
| primary_topic.domain.id | https://openalex.org/domains/3 |
| primary_topic.domain.display_name | Physical Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1605 |
| primary_topic.subfield.display_name | Organic Chemistry |
| primary_topic.display_name | Synthesis and Characterization of Heterocyclic Compounds |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2238074512, https://openalex.org/W3033621138, https://openalex.org/W3101847676, https://openalex.org/W4387523548, https://openalex.org/W3214253064, https://openalex.org/W3110306454, https://openalex.org/W4246044330, https://openalex.org/W4247425301, https://openalex.org/W4387014929 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.54536/ajlsi.v4i1.3268 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4387282411 |
| best_oa_location.source.issn | 2833-1397 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2833-1397 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | American Journal of Life Science and Innovation |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | American Journal of Life Science and Innovation |
| best_oa_location.landing_page_url | https://doi.org/10.54536/ajlsi.v4i1.3268 |
| primary_location.id | doi:10.54536/ajlsi.v4i1.3268 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4387282411 |
| primary_location.source.issn | 2833-1397 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2833-1397 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | American Journal of Life Science and Innovation |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://journals.e-palli.com/home/index.php/ajlsi/article/download/3268/2386 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | American Journal of Life Science and Innovation |
| primary_location.landing_page_url | https://doi.org/10.54536/ajlsi.v4i1.3268 |
| publication_date | 2025-06-15 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 22 |
| abstract_inverted_index.(a | 66 |
| abstract_inverted_index.an | 2, 60 |
| abstract_inverted_index.as | 21 |
| abstract_inverted_index.by | 100, 159, 205, 214 |
| abstract_inverted_index.in | 15, 25, 71, 82, 91, 114, 161, 187, 197, 229 |
| abstract_inverted_index.is | 1 |
| abstract_inverted_index.it | 109, 218, 222 |
| abstract_inverted_index.of | 58, 79, 89, 129, 232 |
| abstract_inverted_index.on | 76 |
| abstract_inverted_index.or | 24 |
| abstract_inverted_index.to | 17, 53, 164, 209 |
| abstract_inverted_index.2.8 | 147 |
| abstract_inverted_index.DNA | 124, 156, 211 |
| abstract_inverted_index.and | 8, 33, 42, 47, 73, 93, 98, 104, 122, 133, 140, 146, 153, 172, 180, 191, 202, 217, 235 |
| abstract_inverted_index.any | 226 |
| abstract_inverted_index.are | 12, 31, 43 |
| abstract_inverted_index.can | 34 |
| abstract_inverted_index.did | 117 |
| abstract_inverted_index.for | 45, 64 |
| abstract_inverted_index.its | 183, 207 |
| abstract_inverted_index.not | 118, 224 |
| abstract_inverted_index.the | 6, 55, 77, 102, 127, 166, 177, 188, 230 |
| abstract_inverted_index.two | 150 |
| abstract_inverted_index.was | 96, 110, 219 |
| abstract_inverted_index.(2.1 | 145 |
| abstract_inverted_index.From | 107 |
| abstract_inverted_index.Geno | 56, 87, 120 |
| abstract_inverted_index.H2O2 | 160 |
| abstract_inverted_index.This | 49 |
| abstract_inverted_index.both | 115, 162, 186, 198 |
| abstract_inverted_index.bulk | 72, 92, 139, 171 |
| abstract_inverted_index.drug | 36 |
| abstract_inverted_index.form | 95, 174 |
| abstract_inverted_index.side | 40 |
| abstract_inverted_index.skin | 7 |
| abstract_inverted_index.that | 112, 221 |
| abstract_inverted_index.used | 14, 44, 144 |
| abstract_inverted_index.with | 27, 84, 137, 149 |
| abstract_inverted_index.Comet | 103, 189 |
| abstract_inverted_index.IgG1k | 68 |
| abstract_inverted_index.aimed | 52 |
| abstract_inverted_index.forms | 116, 199 |
| abstract_inverted_index.human | 67 |
| abstract_inverted_index.ideal | 61 |
| abstract_inverted_index.often | 13 |
| abstract_inverted_index.other | 28 |
| abstract_inverted_index.study | 51 |
| abstract_inverted_index.using | 101 |
| abstract_inverted_index.would | 223 |
| abstract_inverted_index.almost | 165 |
| abstract_inverted_index.cases, | 19 |
| abstract_inverted_index.damage | 125, 157, 179, 212, 228 |
| abstract_inverted_index.groups | 163 |
| abstract_inverted_index.induce | 225 |
| abstract_inverted_index.level. | 169 |
| abstract_inverted_index.reduce | 210 |
| abstract_inverted_index.severe | 18 |
| abstract_inverted_index.showed | 200 |
| abstract_inverted_index.stress | 216 |
| abstract_inverted_index.adverse | 184 |
| abstract_inverted_index.as-says | 193 |
| abstract_inverted_index.assays, | 108 |
| abstract_inverted_index.assays. | 106 |
| abstract_inverted_index.control | 168 |
| abstract_inverted_index.disease | 4 |
| abstract_inverted_index.effects | 185, 204 |
| abstract_inverted_index.enhance | 35 |
| abstract_inverted_index.exhibit | 119 |
| abstract_inverted_index.format. | 142 |
| abstract_inverted_index.further | 227 |
| abstract_inverted_index.healthy | 85, 134, 233 |
| abstract_inverted_index.induced | 158 |
| abstract_inverted_index.joints. | 9 |
| abstract_inverted_index.patient | 131 |
| abstract_inverted_index.reduced | 123, 176 |
| abstract_inverted_index.therapy | 46 |
| abstract_inverted_index.µg/mL) | 148 |
| abstract_inverted_index.Overall, | 195 |
| abstract_inverted_index.biologic | 10, 62 |
| abstract_inverted_index.compared | 99 |
| abstract_inverted_index.effects, | 41 |
| abstract_inverted_index.liposome | 74, 173 |
| abstract_inverted_index.markedly | 175 |
| abstract_inverted_index.moderate | 16 |
| abstract_inverted_index.negative | 167 |
| abstract_inverted_index.observed | 220 |
| abstract_inverted_index.patients | 81 |
| abstract_inverted_index.persons. | 86 |
| abstract_inverted_index.produced | 213 |
| abstract_inverted_index.reducing | 38 |
| abstract_inverted_index.research | 50 |
| abstract_inverted_index.systemic | 39 |
| abstract_inverted_index.toxicity | 57, 88, 121 |
| abstract_inverted_index.Liposomes | 30 |
| abstract_inverted_index.Psoriasis | 0 |
| abstract_inverted_index.affecting | 5 |
| abstract_inverted_index.antibody, | 69 |
| abstract_inverted_index.decreased | 155 |
| abstract_inverted_index.different | 151 |
| abstract_inverted_index.evaluated | 97 |
| abstract_inverted_index.following | 126 |
| abstract_inverted_index.liposomal | 94 |
| abstract_inverted_index.liposomes | 141 |
| abstract_inverted_index.oxidative | 215 |
| abstract_inverted_index.patients. | 236 |
| abstract_inverted_index.potential | 208 |
| abstract_inverted_index.psoriasis | 65 |
| abstract_inverted_index.psoriatic | 80, 130 |
| abstract_inverted_index.research. | 48 |
| abstract_inverted_index.treatment | 63, 128 |
| abstract_inverted_index.versatile | 32 |
| abstract_inverted_index.comparison | 83 |
| abstract_inverted_index.diminished | 182 |
| abstract_inverted_index.expressing | 206 |
| abstract_inverted_index.protective | 203 |
| abstract_inverted_index.retention, | 37 |
| abstract_inverted_index.treatments | 11 |
| abstract_inverted_index.Secukinumab | 90, 113, 138, 143, 170, 196 |
| abstract_inverted_index.combination | 26 |
| abstract_inverted_index.effectively | 154 |
| abstract_inverted_index.individuals | 234 |
| abstract_inverted_index.investigate | 54 |
| abstract_inverted_index.lymphocytes | 78, 132, 136, 231 |
| abstract_inverted_index.monotherapy | 23 |
| abstract_inverted_index.treatments. | 29 |
| abstract_inverted_index.(p<0.01). | 194 |
| abstract_inverted_index.H2O2-induced | 178 |
| abstract_inverted_index.Secukinumab, | 59 |
| abstract_inverted_index.administered | 20 |
| abstract_inverted_index.anti-IL17A), | 70 |
| abstract_inverted_index.demonstrated | 111 |
| abstract_inverted_index.micronucleus | 105, 192 |
| abstract_inverted_index.proficiently | 181 |
| abstract_inverted_index.(p<0.0001) | 190 |
| abstract_inverted_index.nanoparticles | 75 |
| abstract_inverted_index.anti-genotoxic | 201 |
| abstract_inverted_index.individual’s | 135 |
| abstract_inverted_index.concentrations, | 152 |
| abstract_inverted_index.immune-mediated | 3 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| citation_normalized_percentile.value | 0.19130568 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |